论文部分内容阅读
目的：比较替尼泊甙（ＶＭ２６）和卡氮芥（ＢＣＮＵ）分别联合口服环己亚硝脲（ＣＣＮＵ）治疗脑胶质瘤的疗效。方法：对２７例脑胶质瘤手术切除后，采用微导管进行超选择脑动脉灌注法分组灌注ＶＭ２６（Ａ组）和ＢＣＮＵ（Ｂ组），并且两者联合口服ＣＣＮＵ，化疗后，依肿瘤实际体积的变化和平均生存时间观察疗效。结果：Ａ组有效率１２／１５，Ｂ组有效率４／１２，Ａ组和Ｂ组平均生存时间分别为２５．３个月和２１．１个月（Ｐ＜０．０５）。结论：超选择脑动脉灌注ＶＭ２６联合口服ＣＣＮＵ治疗脑胶质瘤疗效高，毒副作用小。
OBJECTIVE: To compare the therapeutic efficacy of teniposide (VM26) and cardatake (BCNU) combined with oral cyclohexylnitrosourea (CCNU) in the treatment of glioma. METHODS: Twenty-seven cases of brain gliomas were surgically resected and microcatheters were used for superselective cerebral arterial perfusion to perfuse VM26 (group A) and BCNU (group B), and both were combined with CCNU. After chemotherapy, the tumors were treated with chemotherapy. The changes in volume and mean survival time were observed for efficacy. Results: The effective rate was 12/15 in group A, 4/12 in group B, and the average survival time in group A and group B was 25.3 months and 21.1 months, respectively (P<0.05). Conclusion: Hyperselective cerebral arterial perfusion VM26 combined with oral CCNU treatment of gliomas is highly effective and has few side effects.